Mary Hamby

Background

About Mary Hamby

Innovative and strategic executive leader in drug discovery and development, dedicated to advancing novel therapeutics with a focus on neuroinflammation and neurodegenerative diseases. Forward-thinking and solutions-oriented, with a strong ability to identify and seize opportunities that drive program success and create synergistic value across company initiatives. Skilled in building and sustaining high-impact KOL collaborations and strategic partnerships. A rigorous scientist with a proven track record of guiding programs from early target discovery through lead optimization, IND-enabling studies, and into Phase 2 clinical trials. Accomplished communicator, adept at engaging diverse stakeholders from scientific teams to investors. Experienced mentor committed to developing high-performing teams. Instrumental in driving successful IPO financing and creating long-termcompany value.Key Areas of Expertise Drug Discovery and Development, Innovation Executive Leadership, Strategic Planning, Site Lead, Building Teams, Team Mentorship Novel Target Identification and Validation, Target Discovery Platforms and Screening Funnels Proof of Concept, Mechanism of Action, Providing Scientific Rationale to Advance Programs Candidate Enablement, IND Filing, FDA briefing packages/meetings Translation, Biomarker Discovery and Clinical Biomarkers Neurodegeneration, Neuroinflammation, Retinal Disorders, Novel Targets Financing, Pitch Decks, IPOsDeep subject matter expertise in R&D for neurodegenerative such as Alzheimer's disease, Parkinson's disease, dementia with Lewy bodies (DLB), as well as geographic atrophy / dry age-related macular degeneration (AMD).Other Areas of Expertise:External Innovation: Identifying, evaluating, and integrating novel external technologies and partnerships.Clinical Biomarkers: Proficient in the development and application of biomarkers for clinical trials, with a focus on plasma and CSF biofluid assessmentsBioinformatics: Leveraging advanced bioinformatics tools to analyze complex datasets and drive insights.Drug Development: Extensive experience in small molecule discovery, clinical candidate selection, pharmacodynamics (PD), pharmacokinetics (PK), and PK/PD modeling.Clinical Trial Design: Expertise in guiding design of robust clinical trials and developing biomarker strategies for early-phase clinical development.Venture Capital & Investor Relations: Experienced in pitching to venture capital firms, creating investor presentations, securing financing, including roadshows and an oversubscribed IPO.